Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1990-05-11
1992-06-16
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514912, A61K 3155
Patent
active
051225220
ABSTRACT:
A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a muscarinic pharmacological antagonist relatively selective for blocking the cholinergic receptors in cells of the brain, neural tissue and/or neural ganglia but less selective for blocking the cholinergic receptors of the cells of smooth muscles at the front of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is pirenzepine. Other suitable antagonists are telenzepine and o-methoxy-sila-hexocyclium.
REFERENCES:
patent: 4616025 (1986-10-01), Ezer et al.
Chem Abst, 101:33056e (1984) Daniotti et al.
S. D. Meriney et al., J. Neuro. Sci. Dec. 1987 pp. 3827-3839, "Cholinergic Innervation of the Smooth Muscle Cells in the Ceroid Coat of the Chick Eye and its Development".
R. Hammer et al., TIPS Jan. 1982, "Selective Muscarinic Receptor Antagonists".
H. A. Perr et al., Gastroenterology (1989) 96:1521-8, "Cyclic Nucleotides Regulate Collagen Production by Human Intestinal Smooth Muscle Cells".
Scandinavian Journal of Gastroenterology, Papers published on Jun. 8, 1980 on "Advances in Basic and Clinical Pharmacology of Pirenzepine".
Heathcote et al. (Scand. J. Gastro. 1980) "Pirenzepine Selectively Inhibits Gastric Acid Secretion: a Comparative Pharmacological Study Between Pirenzepine and Seven Antiacetylcholine Drugs."
Birdsall et al. (Scand. J. Gastro 1980) "Pirenzepine--a Ligant with Original Binding Properties to Muscarinic Receptors".
Jaup, Stockbrugger and Dotevall. (Scand. J. Gastro 1980) "Comparison of the Action of Pirenzepine and L-Hyoscyamine on Gastric Acid Secretion and Other Muscarinic Effects".
Jaup and Blomstrand, (Scand. J. Gastro. 1980) "Cerebrospinal Fluid Concentration of Pirenzepine After Therapeutic Dosage".
J. J. Hagan et al. (CNS Pharmacology Labs) "The Relative Potencies of Cholinomimetics and Muscarinic Antagonists on the Rat Iris in Vivo": Effects of pH on Potency of Pirenzepine and Telenzepine (1988).
C. Schudt, Euro. Journal of Pharmacology 165 (1989) pp. 87-96, "The Affinity, Selectivity and Biological activity of Telenzepine Enantiomers".
Noel Buckley et al. Am. Soc. for Pharmacology and Experimental Therapeutics 35:469-476 Antagonist Binding Properties of Five Cloned Muscarinic Receptors Expressed in CHO K1 Cells (1989).
Gunter Lambrecht et al. Euro. Journal of Pharmacology 151 (1988) 155-156, "o-Methyoxy-sila-hexocyclium: a New Quarternary M.sub.1 -selective Muscarinic Antagonist".
Abstract 71.14 by R. A. Stone et al. "Altered Retinal Amine Neurotransmitters in Form-Deprivation Myopia", Soc. Neurosci, Abstr. vol. 13, part I, p. 240, for meeting Nov. 16-21, 1987.
Abstract 36 by R. A. Stone et al., "Altered Dopamine Metabolism and Form-Deprivation Myopia:" , Invest. Ophth. Vis. Sci., 29 33, for meeting May 1-6, 1988.
E. Raviola et al., "An Animal Model of Myopia" N.E. Journ. Med. vol. 132, No. 25 (1985).
D. A. Goss, "Attempts to Reduce the Rate of Increase of Myopia in Young People--A Critical Literature Review", Am. Jour. of Optom. & Physc. Optics, vol. 59, No. 10, pp. 828-841 (1982).
B. J. Curtin, "The Myopias--Basic Science and Chemical Management" Harper & Row (1985) pp. 220-225.
M. L. Rubin et al. "Myopia--A Treatable Disease?" Survey of Opthal. vol. 21, No. 1 (Jul.-Aug. 1976).
Laties Alan M.
Stone Richard A.
Fay Zohreh A.
The Trustees of the University of Pennsylvania
Waddell Frederick E.
LandOfFree
Treatment and control of ocular development does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and control of ocular development, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and control of ocular development will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1753990